For research use only. Not for therapeutic Use.
Raleukin (AMG-719) is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Raleukin (AMG-719) is the first biological agent to block the pro-inflammatory effects[1][2].
Combined Etanercept (5 mg/kg, ip) and Anakinra (100 mg/kg, ip. daily for 7 days) substantially improves marginal mass human islet engraftment in immunodeficient mice[2].
Raleukin (AMG-719) enhances tumor growth inhibition in mice receiving peptide vaccination and β-(1-3),(1-6)-D-glucan[3].
| Catalog Number | M091621 |
| CAS Number | 143090-92-0 |
| Molecular Formula | C759H1186N208O232S10 |
| Purity | ≥95% |
| Reference | [1]. Cvetkovic RS, et al. Anakinra. BioDrugs. 2002;16(4):303-11; discussion 313-4. [2]. McCall M, et al. Anakinra potentiates the protective effects of etanercept in transplantation of marginal mass human islets in immunodeficient mice. Am J Transplant. 2012 Feb;12(2):322-9. [3]. Harnack U, et al. IL-1 receptor antagonist anakinra enhances tumour growth inhibition in mice receiving peptide vaccination and beta-(1-3),(1-6)-D-glucan. Anticancer Res. 2010 Oct;30(10):3959-65. |
